tenofovir disoproxil

This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy

Latest news

GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
ViiV starts trial of HIV-preventing injections for women

can defend against the spread of the virus as well as daily dosing with Gilead’s oral pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil).
People at-risk of HIV in England could get PrEP from September

The study of Gilead's pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil) - which was approved by the EMA last year - follows a pilot that saw the drug prevent
Gilead plans fightback against HIV arch-rival ViiV

The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in Descovy - emtricitabine and tenofovir alafenamide - met its main objective of non-inferiority to ViiV Healthcare's ... The drug is an upgrade to
Gilead's Hepatitis B therapy Vemlidy granted EU approval

Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

More from news
Approximately 5 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Systematic Reviewer - Oxford: Negotiable

Editorial Manager - MedComms: DOE

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Healthcare Communications Account Directors x 2: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Associate Director: £75, 000-90, 000

Experienced Medical Writers: Competitive Salary and Benefits

Account Manager- Healthcare Advertising: Negotiable

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager: Competitive Salary Offered

Principal Health Economist - North-West: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Manager: Negotiable

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: Competitive Salary Offered

Account Manager / Account Director: Competative

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Subscribe to our email news alerts

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...